Literature DB >> 19131119

Sepsis-From human organ failure to laminar failure.

J K Belknap1, J N Moore, E C Crouser.   

Abstract

The horse with gram negative sepsis is known to be at particular risk of succumbing to laminitis. This review summarizes recent evidence indicating that similar pathologic events relating to inflammatory injury occur in laminar failure in laminitis as occur in organ injury/failure in human sepsis. The discussion also points out some important differences between the laminae and target organs in human sepsis that impact the clinical nature of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 19131119     DOI: 10.1016/j.vetimm.2008.11.013

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

Review 1.  Metabolic syndrome: is equine disease comparable to what we know in humans?

Authors:  Antonia Ertelt; Ann-Kristin Barton; Robert R Schmitz; Heidrun Gehlen
Journal:  Endocr Connect       Date:  2014-06-03       Impact factor: 3.335

2.  Effect of Delayed Digital Hypothermia on Lamellar Inflammatory Signaling in the Oligofructose Laminitis Model.

Authors:  K Dern; M Watts; B Werle; A van Eps; C Pollitt; J Belknap
Journal:  J Vet Intern Med       Date:  2017-02-01       Impact factor: 3.333

3.  Blood glucose is unlikely to be a prognostic biomarker in acute colitis with systemic inflammatory response syndrome in Thoroughbred racehorses.

Authors:  Shuntaro Urayama; Daisuke Arima; Fumiaki Mizobe; Yuta Shinzaki; Motoi Nomura; Yohei Minamijima; Kanichi Kusano
Journal:  J Equine Sci       Date:  2018-03-23

4.  The Contribution of Adipose Tissue-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma to the Treatment of Chronic Equine Laminitis: A Proof of Concept.

Authors:  Mario Angelone; Virna Conti; Cristiano Biacca; Beatrice Battaglia; Laura Pecorari; Francesco Piana; Giacomo Gnudi; Fabio Leonardi; Roberto Ramoni; Giuseppina Basini; Silvia Dotti; Sabrina Renzi; Maura Ferrari; Stefano Grolli
Journal:  Int J Mol Sci       Date:  2017-10-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.